Novo Nordisk Soars 12% as OMX Copenhagen Index Climbs 6% Amid Eli Lilly's Setback

The OMX Copenhagen 20 index surged over 6%, driven by Novo Nordisk's 12% jump after Eli Lilly's weight-loss drug trial results disappointed, causing Lilly's shares to drop 12.9%. N...